Inventor · disambiguated record
Subhash Desai
Also filed as: DESAI SUBHASH
12 granted patents·15 pending applications·221 citations·filing 1987–2019
92Inventor score
Top patents by PatentIndex Score
27 records- 0182US9511037B2Compositions for reduction of side effectsDESAI SUBHASH·Filed 2012·Granted Dec 6, 2016·7 cites·21 claims
- 0280US7172769B2Cyclooxygenase-2 inhibitor compositions having rapid onset of therapeutic effectPHARMACIA CORP·Filed 2000·Granted Feb 6, 2007·13 cites·17 claims
- 0380US4814179AFloating sustained release therapeutic compositionsUNIV ST JOHNS·Filed 1987·Granted Mar 21, 1989·67 cites·7 claims
- 0475US7220434B2Dual-release compositions of a cyclooxygenase-2 inhibitorPHARMACIA CORP OF PFIZER INC·Filed 2000·Granted May 22, 2007·19 cites·18 claims
- 0574US10912744B2Therapeutic formulation for reduced drug side effectsKEMPHARM INC·Filed 2019·Granted Feb 9, 2021·0 cites·6 claims
- 0668US5609884AControlled release naproxen sodium plus naproxen combination tabletSEARLE & CO·Filed 1992·Granted Mar 11, 1997·29 cites·12 claims
- 0764US5756125AControlled release naproxen sodium plus naproxen combination tabletSEARLE & CO·Filed 1995·Granted May 26, 1998·18 cites·14 claims
- 0858US4814178AFloating sustained release therapeutic compositionsBOLTON SANFORD·Filed 1987·Granted Mar 21, 1989·31 cites·7 claims
- 0952US5618559AMethod of making modified-release metronidazole compositionsSEARLE & CO·Filed 1995·Granted Apr 8, 1997·12 cites·9 claims
- 1052US2005250748A1Combination therapy of angiotensin converting enzyme inhibitor and eplerenone for treatment of cardiovascular diseaseSEARLE & CO·Filed 2003·Application pending·0 cites
- 1150US2007202170A1Dual-release compositions of a cyclooxygenase-2 inhibitorPHARMACIA CORP·Filed 2007·Application pending·0 cites
- 1249US6103262AModified-release metronidazole compositions and methods for making and using sameSEARLE & CO·Filed 1994·Granted Aug 15, 2000·15 cites·35 claims
- 1348US10463633B2Therapeutic formulation for reduced drug side effectsDESAI SUBHASH·Filed 2011·Granted Nov 5, 2019·0 cites·6 claims
- 1448US2003212053A1Nanoparticulate eplerenone compositionsFiled 2003·Application pending·0 cites
- 1548US2005261261A1Eplerenone drug substance having high phase purityPHARMACIA CORP·Filed 2005·Application pending·0 cites
- 1648US2002142045A1Cyclooxygenase-2 inhibitor compositions having rapid onset of therapeutic effectFiled 2002·Application pending·0 cites
- 1747US6030643APotassium, sodium and tris oxaprozin salt pharmaceutical formulationsSEARLE & CO·Filed 1997·Granted Feb 29, 2000·10 cites·36 claims
- 1846US2003064098A1Cyclooxygenase-2 inhibitor compositions having rapid onset of therapeutic effectFiled 2001·Application pending·0 cites
- 1945US2009149431A1Eplerenone Drug Substance Having High Phase PurityBARTON KATHLEEN P·Filed 2009·Application pending·0 cites
- 2045US2017105983A1Compositions for reduction of side effectsGENCO SCIENCES LLC·Filed 2016·Application pending·0 cites
- 2144US2002006919A1Nanoparticulate eplerenone compositionsFiled 2000·Application pending·0 cites
- 2243US2004077611A1Triple therapy of angiotensin converting enzyme inhibitor epoxy-steroidal aldosterone antagonist and diuretic or digoxin for treatment of cardiovascular diseaseSEARLE & CO·Filed 2003·Application pending·0 cites
- 2343US2005159594A1Eplerenone crystal form exhibiting enhanced dissolution ratePHARMACIA CORP·Filed 2004·Application pending·0 cites
- 2442US2003083493A1Eplerenone drug substance having high phase purityFiled 2002·Application pending·0 cites
- 2541US2005267302A1Eplerenone crystalline form exhibiting enhanced dissolution rateSEARLE & CO·Filed 2003·Application pending·0 cites
- 2634US2002045746A1Eplerenone crystalline formFiled 2000·Application pending·0 cites
- 2734US2002038021A1Eplerenone crystalline form exhibiting enhanced dissolution rateFiled 2000·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Subhash Desai files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →